You are here: Industry Insights > Osteoporosis

News List

Osteoporosis drug could treat human hair loss europeanpharmaceuticalreview
May 11, 2018
A new drug could ease the distress of men and women who suffer from baldness…
"Females are at higher risk of suffering from osteoporosis" biospectrumasia
December 08, 2017
The age- and sex- adjusted hip fracture rates have exploded in Asia due to urbanization, and the much-improved survival rates in Asians. By 2050, Asia will account for 50% of the world’s hip fractures.
Healthcare community join to fight fragility fractures caused by Osteoporosis biospectrumasia
October 11, 2017
The ‘Fight the Fracture’ public education campaign aims to empower patients who have suffered a fracture, help them understand and mitigate their risk of a second fracture.
Romosozumab provides protection against fractures in osteoporosis europeanpharmaceuticalreview
September 22, 2017
A new treatment for osteoporosis provides major improvements in bone density and fractures than the current standard treatment…
Amgen submits sBLA for Prolia in glucocorticoid-induced osteoporosis cphi-online
August 01, 2017
Results from the Phase III study included in the sBLA submission showed that treatment with Prolia for 12 months led to statistically significant greater gains in BMD at the lumbar spine and total hip compared to risedronate.
FDA refuses approval of Amgen osteoporosis drug pharmafile
July 18, 2017
Amgen and its development partner UCB have announced that the FDA has issued a complete response letter for the biologics license application for their osteoporosis drug Evenity (romosozumab), refusing to approve the treatment for use in postmenopausal fe
Potential early warning signs of osteoporosis found in South Asian women biospectrumasia
March 22, 2017
Researchers will now undertake an investigation into bone formation, assessing activity of the osteoblast cells which form bone tissue
Radius Health Receives Notification of PDUFA Extension for Abaloparatide-SC drugs.com
March 13, 2017
Radius Health announced that the U.S. Food and Drug Administration (FDA) will require additional time to complete its review of the New Drug Application (NDA) for Abaloparatide-SC.

Previous page 1 2 3 4 Next page